HMGCR and metabolic syndrome: Another potential link between dyslipidemia and hematological cancer is the rising evidence for the fact that inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-CoA reductase)—commonly used in the treatment of hyperlipidemia—were found to have anti-myeloma activity, both, in vivo (77–80) and in vitro (81–85), probably by inducing apoptosis of myeloma cells.